Prognostic impact of FLT3 ‐ITD mutation on NPM1 + acute myeloid leukaemia patients and related molecular mechanisms
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18973 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Xin'an Pan und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Insti…. Hauptthemen laut MEDLINE: Nuclear Proteins, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
The prognosis of acute myeloid leukaemia (AML) patients carrying NPM1 mutations is significantly worse when accompanied by FLT3 ‐ITD mutations. However, accurate quantitative detection of FLT3 ‐ITD mutations remains challenging. To identify a novel biomarker in NPM1 + FLT3 ‐ITD + AML patients for more accurate stratification, we analysed the differential gene expression between the NPM1 + FLT3 ‐ITD + and NPM1 + FLT3 ‐ITD − groups in five public AML datasets and identified a biomarker by taking the intersection of differentially expressed genes. We validated this biomarker in bone marrow samples from NPM1 + AML patients at the Peking University Institute of Haematology and analysed its prognostic significance. BCAT1 expression was higher in the NPM1 + FLT3 ‐ITD + group than in the NPM1 + FLT3 ‐ITD − group in all seven cohorts. BCAT1 was able to predict the prognosis of NPM1 + FLT3 ‐ITD + AML patients, and its predictive ability was superior to that of the FLT3 ‐ITD allelic ratio (AR). FLT3 ‐targeted inhibitor quizartinib reduced BCAT1 expression. BCAT1 knockdown using lentiviral vectors led to the downregulation of MYC expression. Thus, we identified BCAT1 as a novel biomarker for NPM1 + FLT3 ‐ITD + AML patients. The FLT3 ‐ITD/ BCAT1 / MYC signalling pathway may play a biological role in promoting the occurrence and development of AML in FLT3 ‐ITD + cell lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, Chin…
- Peking-Tsinghua Center for Life Sciences, Beijing, China.
- Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China.
ORCID-Profile: Guorui Ruan, Qian Jiang, Xiaosu Zhao
Zitieren
APA
Pan, X., Chang, Y., Ruan, G., Wei, F., Jiang, H., Jiang, Q., Huang, X., & Zhao, X. (2023). Prognostic impact of FLT3 ‐ITD mutation on NPM1 + acute myeloid leukaemia patients and related molecular mechanisms. British Journal of Haematology. https://doi.org/10.1111/bjh.18973
Vancouver
Pan X, Chang Y, Ruan G, Wei F, Jiang H, Jiang Q, et al. Prognostic impact of FLT3 ‐ITD mutation on NPM1 + acute myeloid leukaemia patients and related molecular mechanisms. British Journal of Haematology. 2023. doi:10.1111/bjh.18973
BibTeX
@article{Pan2023,
author = {Pan, Xin'an and Chang, Yingjun and Ruan, Guorui and Wei, Fangfang and Jiang, Hao and Jiang, Qian and Huang, Xiaojun and Zhao, Xiaosu},
title = {Prognostic impact of FLT3 ‐ITD mutation on NPM1 + acute myeloid leukaemia patients and related molecular mechanisms},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18973}
}
EUVIMED